PFSA Key Statistics, Chart & Performance
The current stock price of PFSA is 0.1693 USD. In the past month the price decreased by -34.38%.
PFSA Latest News, Press Relases and Analysis
PFSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.83 | 224.35B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.61 | 205.58B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.43 | 150.52B | ||
| SYK | STRYKER CORP | 28.18 | 141.91B | ||
| IDXX | IDEXX LABORATORIES INC | 59.7 | 60.23B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.72 | 50.29B | ||
| RMD | RESMED INC | 25.84 | 37.34B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.43 | 36.44B | ||
| DXCM | DEXCOM INC | 34.12 | 24.89B | ||
| PODD | INSULET CORP | 71.6 | 23.02B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 12.05 | 19.32B |
Related stock screener links
About PFSA
Company Profile
Profusa, Inc. engages in the biofeedback for chronic disease management and healthy living services. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-12-20. The firm is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
Company Info
PROFUSA INC
207 West 25Th St, 9Th Floor
New York City NEW YORK US
Employees: 0
Phone: 12124949022
PROFUSA INC / PFSA FAQ
Can you describe the business of PROFUSA INC?
Profusa, Inc. engages in the biofeedback for chronic disease management and healthy living services. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-12-20. The firm is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
Can you provide the latest stock price for PROFUSA INC?
The current stock price of PFSA is 0.1693 USD. The price increased by 5.81% in the last trading session.
What is the dividend status of PROFUSA INC?
PFSA does not pay a dividend.
What is the ChartMill technical and fundamental rating of PFSA stock?
PFSA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the sector and industry classification for PROFUSA INC?
PROFUSA INC (PFSA) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
How many employees does PROFUSA INC have?
PROFUSA INC (PFSA) currently has 0 employees.
PFSA Technical Analysis
PFSA Financial Highlights
Over the last trailing twelve months PFSA reported a non-GAAP Earnings per Share(EPS) of -3. The EPS decreased by -1184% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -856.63% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |